Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.79 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.79 |
| ▸ | GAA | P10253 | 2/20 | 0.79 |
| ▸ | CA1 | P00915 | 2/20 | 0.68 |
| ▸ | CA2 | P00918 | 2/20 | 0.68 |
| ▸ | PGR | P06401 | 2/20 | 0.63 |
| ▸ | NPC1 | O15118 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 3/20 | 0.56 |
| ▸ | KIF11 | P52732 | 2/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.55 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4668688 | 0.94 | LMNA (0.72) | LMNAMAPK1GAACA1CA2 | |
| SCHEMBL3116450 | 0.94 | PGR (0.73) | LMNAMAPK1GAACA1CA2 | |
| SCHEMBL24689849 | 0.89 | LMNA (0.66) | LMNAMAPK1GAACA1CA2 | |
| SCHEMBL3985582 | 0.89 | LMNA (0.76) | LMNAMAPK1GAACA1CA2 | |
| SCHEMBL3468171 | 0.88 | LMNA (0.64) | LMNAMAPK1GAACA1CA2 | |
| SCHEMBL28082142 | 0.88 | RAB9A (0.73) | LMNAMAPK1GAACA1CA2 | |
| SCHEMBL11708669 | 0.84 | CA1 (0.70) | LMNAMAPK1GAACA1CA2 | |
| SCHEMBL4205144 | 0.84 | PGR (0.85) | LMNAMAPK1GAACA1CA2 | |
| SCHEMBL12054668 | 0.83 | KEAP1 (0.75) | LMNAMAPK1GAACA1CA2 | |
| SCHEMBL19313475 | 0.83 | PLAU (0.59) | LMNAMAPK1GAACA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3328843-B1 | 1,3,4-OXADIAZOLE SULFONAMIDE DERIVATIVE COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND THE PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | CHONG KUN DANG PHARMACEUTICAL CORP (KR) | 2022-10-26 | — | — | EP | disclosed |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2022-05-17 | — | — | US | disclosed |
| CN-111848463-B | Camphor sulfanilamide oxime ether compound and preparation method and application thereof | 南京林业大学 | 2022-03-01 | — | — | CN | disclosed |
| EP-3838903-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2021-06-23 | — | — | EP | disclosed |
| CN-107922362-B | 1,3, 4-oxadiazole sulfonamide derivative compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions containing the same | 株式会社钟根堂 | 2021-06-15 | — | — | CN | disclosed |
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2020-10-29 | — | — | US | disclosed |
| WO-2020146657-A1 | PI4-KINASE INHIBITORS WITH ANTI-CANCER ACTIVITY | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2020-07-16 | — | — | WO | disclosed |
| US-10640508-B2 | Diazene directed modular synthesis of compounds with quaternary carbon centers | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190119286-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-04-25 | — | — | US | disclosed |
| EP-3466953-A1 | PYRROLO[2,3-D]PYRIMIDINE DERIVATIVE AS JANUS KINASE INHIBITOR | Incyte Holdings Corporation (US) | 2019-04-10 | — | — | EP | disclosed |
| EP-2343299-A1 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | Incyte Corporation (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7598257-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080167347-A1 | Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives | SHIONGI & CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| US-20080167347-A1 | Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives | SHIONGI & CO., LTD. (JP) | 2008-07-10 | — | — | US | disclosed |
| EP-1839655-A1 | CTGF EXPRESSION INHIBITOR | Shionogi Co., Ltd. (JP) | 2007-10-03 | — | — | EP | disclosed |
| WO-2007070514-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-B]PYRIDINES AND PYRROLO[2,3-B]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | INCYTE CORPORATION | 2007-06-14 | — | — | US | disclosed |
| US-20070031358-A1 | Cosmetic formulations comprising diketo diphenyl pyrrolo-pyrrole pigments | CIBA SPECIALTY CHEMICALS CORP. | 2007-02-08 | — | — | US | disclosed |
| US-20070031358-A1 | Cosmetic formulations comprising diketo diphenyl pyrrolo-pyrrole pigments | CIBA SPECIALTY CHEMICALS CORP. | 2007-02-08 | — | — | US | disclosed |
| WO-1994002463-A1 | ANTIHYPERTENSIVE 1,4-DIHYDROPYRIDINE DERIVATIVES AND PROCESS FOR THEIR PREPARATION | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200338077-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | LMNA 4785/4885MAPK1 285/4885GAA 4364/4885 |
| US-20070031358-A1 | Cosmetic formulations comprising diketo diphenyl pyrrolo-pyrrole pigments | TYR, LAGE3, KRT18 | LMNA 2466/4885MAPK1 2803/4885GAA 759/4885 |
| US-20190119286-A1 | DIAZENE DIRECTED MODULAR SYNTHESIS OF COMPOUNDS WITH QUATERNARY CARBON CENTERS | CSPP1, CBR3, NPY2R | LMNA 2174/4885MAPK1 1596/4885GAA 4222/4885 |
| US-20070135461-A1 | 3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; immune-related diseases, skin disorders, myeloid proliferative disorders, cancer | JAK1, JAK3, MAP3K4 | LMNA 4541/4885MAPK1 90/4885GAA 4524/4885 |
| US-20080167347-A1 | Antidiabetic, antiproliferative, anticancer agents; benzanilide derivatives | CCNY, HDGF, GLI1 | LMNA 2426/4885MAPK1 609/4885GAA 789/4885 |
| US-10640508-B2 | Diazene directed modular synthesis of compounds with quaternary carbon centers | CSPP1, CBR3, NPY2R | LMNA 2174/4885MAPK1 1596/4885GAA 4222/4885 |
| US-11331320-B2 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | JAK3, JAK1, JAK2 | LMNA 4785/4885MAPK1 285/4885GAA 4364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.